Literature DB >> 1587745

Retrospective analysis of 5037 patients with nasopharyngeal carcinoma treated during 1976-1985: overall survival and patterns of failure.

A W Lee1, Y F Poon, W Foo, S C Law, F K Cheung, D K Chan, S Y Tung, M Thaw, J H Ho.   

Abstract

This is a retrospective analysis of 5037 patients with squamous cell carcinoma of the nasopharynx treated during the years 1976-1985. The stage distribution according to Ho's classification was 9% Stage I, 13% II, 50% III, 22% IV, and 6% Stage V. Only 4488 (89%) patients had a full course of megavoltage radiation therapy. The median equivalent dose to the nasopharyngeal region was 65 Gy and cervical region in node-positive patients 53 Gy. Seventy percent (906/1290) of the node-negative patients had no prophylactic neck irradiation. The overall actuarial 10-year survival rate was 43%, and the corresponding failure-free survival 34%. Altogether, 4157 (83%) patients achieved complete remission lasting more than 6 months, but 53% (2205/4157) of them relapsed after a median interval of 1.4 years. The 10-year actuarial local, regional, and distant failure-free rates were 61%, 64%, and 59%, respectively. Thirty-eight percent (338/891) of all patients with local recurrence achieved second local remission. The local complete remission rate with aggressive re-irradiation alone was 47% (333/706). But 37% (124/338) of the responders recurred the second time. The incidence of distant failure correlated significantly with both the N-stage and the T-stage, with the highest (57%) occurring in patients with N3 disease. The incidence of nodal relapse in node-negative patients was 11% (44/384) among those given prophylactic neck irradiation, but 40% (362/906) among those without. Therapeutic irradiation achieved a complete regional remission rate of 90% (306/339). However, despite successful salvage, these patients had a significantly higher distant failure rate than those without nodal relapse, even if they remained local-failure-free (21% vs 6%). Patients treated during 1981-1985 achieved significantly better treatment results than those treated during 1976-1980, especially in terms of the overall survival (57% vs 47% at 5-year), the overall failure-free survival (42% vs 35% at 5-year), and the local failure-free rate (70% vs 63% at 5-year). The possible contributing factors are discussed.

Entities:  

Mesh:

Year:  1992        PMID: 1587745     DOI: 10.1016/0360-3016(92)90740-9

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  152 in total

1.  Update on nasopharyngeal carcinoma.

Authors:  Lester D R Thompson
Journal:  Head Neck Pathol       Date:  2007-11-27

2.  Proof of principle of ocular sparing in dogs with sinonasal tumors treated with intensity-modulated radiation therapy.

Authors:  Jessica A Lawrence; Lisa J Forrest; Michelle M Turek; Paul E Miller; T Rockwell Mackie; Hazim A Jaradat; David M Vail; Richard R Dubielzig; Richard Chappell; Minesh P Mehta
Journal:  Vet Radiol Ultrasound       Date:  2010 Sep-Oct       Impact factor: 1.363

3.  Ifosfamide-based chemotherapy in locoregionally advanced nasopharyngeal cancer: evaluation of its role as neoadjuvant chemotherapy.

Authors:  Sarbani Ghosh-Laskar; Jai Prakash Agarwal; Pranshu Mohindra; Manju Sengar; Shilpa Vyas; V R Pai; Ashwini Budrukkar; Prathamesh Pai; Anil K D'Cruz; Ketayun Ardeshir Dinshaw
Journal:  Med Oncol       Date:  2008-12-02       Impact factor: 3.064

4.  Radiation therapy combined with (or without) cisplatin-based chemotherapy for patients with nasopharyngeal cancer: 15-years experience of a single institution in Korea.

Authors:  Yeon-Sil Kim; Bum-Soo Kim; So-Lyoung Jung; Yeon-Soo Lee; Min-Sik Kim; Dong-Il Sun; Eun-Jung Yoo; Seong-Kwon Mun; Sei-Chul Yoon; Su-Mi Chung; Hoon-Kyo Kim; Seung-Ho Jo; Jin-Hyoung Kang
Journal:  Cancer Res Treat       Date:  2008-12-31       Impact factor: 4.679

5.  Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225.

Authors:  Nancy Lee; Jonathan Harris; Adam S Garden; William Straube; Bonnie Glisson; Ping Xia; Walter Bosch; William H Morrison; Jeanne Quivey; Wade Thorstad; Christopher Jones; K Kian Ang
Journal:  J Clin Oncol       Date:  2009-06-29       Impact factor: 44.544

6.  Epstein-Barr-virus-encoded LMP2A induces primary epithelial cell migration and invasion: possible role in nasopharyngeal carcinoma metastasis.

Authors:  Dirk M Pegtel; Aravind Subramanian; Tzung-Shiahn Sheen; Ching-Hwa Tsai; Todd R Golub; David A Thorley-Lawson
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

7.  Urokinase-type plasminogen activator receptor signaling is critical in nasopharyngeal carcinoma cell growth and metastasis.

Authors:  Ying-Na Bao; Xue Cao; Dong-Hua Luo; Rui Sun; Li-Xia Peng; Lin Wang; Yong-Pan Yan; Li-Sheng Zheng; Ping Xie; Yun Cao; Ying-Ying Liang; Fang-Jing Zheng; Bi-Jun Huang; Yan-Qun Xiang; Xing Lv; Qiu-Yan Chen; Ming-Yuan Chen; Pei-Yu Huang; Ling Guo; Hai-Qiang Mai; Xiang Guo; Yi-Xin Zeng; Chao-Nan Qian
Journal:  Cell Cycle       Date:  2014-04-24       Impact factor: 4.534

8.  Alternative endpoints to the 5-year overall survival and locoregional control for nasopharyngeal carcinoma: A retrospective analysis of 2,450 patients.

Authors:  Chen Chen; Wei Yi; Jin Gao; Xiao-Hui Li; Lu-Jun Shen; Bo-Fei Li; Zi-Wei Tu; Ya-Lan Tao; Chang-Bin Jiang; Yun-Fei Xia
Journal:  Mol Clin Oncol       Date:  2014-02-20

9.  Anti-oncogenic activity of Chibby in the development of human nasopharyngeal carcinoma.

Authors:  Cheng-Fu Cai; Li-Man Liu; Han-Jing Shangguan; Cun-Shan Liu; Xian-Yang Luo; Yi-Meng Li
Journal:  Oncol Lett       Date:  2018-02-09       Impact factor: 2.967

10.  Outcomes of nasopharyngeal carcinoma screening for high risk family members in Hong Kong.

Authors:  Wai Tong Ng; Cheuk Wai Choi; Michael C H Lee; Lai Yau Law; Tsz Kok Yau; Anne W M Lee
Journal:  Fam Cancer       Date:  2010-06       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.